Cancer screening guidelines reflect the costs and benefits of population-based screening based on evidence from clinical trials. While most of the existing literature on compliance with cancer screening guidelines only measures raw screening rates in the target age groups, we used a novel approach to estimate degree of guideline compliance across Canadian provinces for breast, colorectal and prostate cancer screening. Measuring compliance as the change in age-specific screening rates at the guideline-recommended initiation age (50), we generally found screening patterns across Canadian provinces that were not consistent with guideline compliance.
We calculated age-cancer-specific screening rates for ages 40-60 using the Canadian Community Health Survey (2003 and 2005), a cross-sectional, nationally representative survey of health status, health care utilization and health determinants in the Canadian population. We estimated the degree of compliance using logistic regression to measure the change in adjusted screening rates at the guideline-recommended initiation age for each province in the sample.
For breast cancer, after adjusting for age trends and other covariates, being above age 50 in Quebec increased the probability of being screened by 19 percentage points, from an average screening rate of 24% among 40-49 year olds. None of the other regions exhibited a statistically significant change in screening rates at age 50. Additional analyses indicated that these patterns reflect asymptomatic screening and that Quebec's breast cancer screening program enhanced the degree of guideline compliance in that province. Colorectal cancer screening practice was consistent with guidelines only in Saskatchewan, as screening rates increased at age 50 by 12 percentage points, from an average rate of 6% among 40-49 year olds. For prostate cancer, the regions examined here are not compliant with Canadian guidelines since screening rates were quite high, and there was not a discrete increase at any particular age.
Screening practice for breast, colorectal and prostate cancer was generally not consistent with Canadian clinical guidelines. Quebec (breast) and Saskatchewan (colorectal) were exceptions to this, and the impact of Quebec's breast cancer screening program suggests a role for policy in improving screening guideline compliance.
Notes
Cites: CMAJ. 2000 Oct 31;163(9):1133-811079057
Cites: N Engl J Med. 2009 Mar 26;360(13):1320-819297566
Cites: CMAJ. 2001 Feb 20;164(4):469-7611233866
Cites: CMAJ. 2001 Jul 24;165(2):206-811501466
Cites: Cancer Detect Prev. 2002;26(5):350-6112518865
Cites: Am J Epidemiol. 2003 May 15;157(10):940-312746247
Cites: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1182-714652278
Cites: Can J Public Health. 1996 May-Jun;87(3):176-808771920
Cites: J Med Screen. 1998;5(2):73-809718525
Cites: CMAJ. 1998 Oct 6;159(7):797-89805027
Cites: Chronic Dis Can. 1998;19(3):112-309820835
Cites: Can J Public Health. 2005 Sep-Oct;96(5):364-816238156
Cites: Can J Public Health. 2006 May-Jun;97(3):171-616827400
Cites: Eur J Cancer Prev. 2008 Feb;17(1):48-5318090910
Cites: Can J Urol. 2007 Dec;14(6):3727-3318163923
Cites: BMC Gastroenterol. 2007;7:3917910769
Cites: Womens Health Issues. 2008 Mar-Apr;18(2):85-9918182305
Cites: N Engl J Med. 2009 Mar 26;360(13):1310-919297565